Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 79.70M | 60.11M | 89.30M | 39.31M | 54.64M |
Gross Profit | 38.70M | -11.68M | 26.21M | -10.68M | 6.64M |
EBITDA | -19.42M | -104.29M | -7.82M | -73.04M | -11.14M |
Net Income | -20.99M | -108.35M | -11.38M | -74.74M | -7.77M |
Balance Sheet | |||||
Total Assets | 66.75M | 65.60M | 125.94M | 105.92M | 161.51M |
Cash, Cash Equivalents and Short-Term Investments | 17.52M | 26.05M | 16.31M | 27.88M | 26.03M |
Total Debt | 7.00M | 4.41M | 4.92M | 4.16M | 4.59M |
Total Liabilities | 29.88M | 23.92M | 37.73M | 18.90M | 29.61M |
Stockholders Equity | 36.87M | 41.68M | 88.21M | 87.02M | 131.90M |
Cash Flow | |||||
Free Cash Flow | -26.52M | -46.74M | -9.93M | -23.24M | -22.14M |
Operating Cash Flow | -26.33M | -46.49M | -9.37M | -22.63M | -21.92M |
Investing Cash Flow | -189.82K | -4.25M | -1.56M | -5.60M | -8.70M |
Financing Cash Flow | 17.99M | 60.48M | -643.21K | 30.09M | 33.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | AU$96.86M | 21.40 | 6.80% | 2.59% | 15.48% | 135.65% | |
65 Neutral | $26.91B | 15.40 | -4.43% | 2.85% | 1.05% | 4.97% | |
49 Neutral | AU$22.00M | ― | -47.74% | ― | 43.14% | 51.35% | |
48 Neutral | AU$151.83M | ― | -21.85% | ― | 30.54% | 88.42% | |
42 Neutral | AU$34.64M | ― | ― | 4.22% | -199.40% | ||
― | €17.45M | ― | -23.00% | ― | ― | ― | |
47 Neutral | AU$22.31M | ― | -33.40% | ― | -13.09% | -139.06% |
Bubs Australia Ltd. has appointed Joe Coote as its new Chief Executive Officer, effective immediately. Coote, with over 20 years of leadership experience in the FMCG, dairy, and infant nutrition sectors, is expected to drive the company’s domestic and international growth. His extensive expertise and global networks are anticipated to support Bubs’ strategic priorities and expansion plans, particularly as the company aims to secure permanent market access in the USA later in 2025.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. reported significant financial growth for the fiscal year 2025, with a 29% increase in net revenue to $102.5 million and a positive EBITDA of $5.5-$6 million, marking a turnaround from the previous year’s loss. The company also achieved positive operating cash flow and has substantial cash reserves. The US market led growth with a 52% increase in revenue, while China, Australia, and other international markets also showed strong performance. Bubs’ submission to the US FDA for its New Infant Formula is expected to enhance its market presence further.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced the issuance of over 10 million unquoted securities as part of an employee incentive scheme, set to vest in June 2027. This move is likely aimed at aligning employee interests with long-term company performance, potentially impacting the company’s operational strategy and market positioning by fostering a motivated workforce.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. has submitted its New Infant Formula Submission to the US FDA, marking a crucial step towards securing permanent regulatory approval in the US market. This move is part of Bubs’ strategy to solidify its position in the US, its largest market, and is expected to enhance its growth prospects. The successful completion of a large-scale clinical trial in the US underscores Bubs’ technical and operational capabilities, positioning it as a credible global manufacturer in the dairy industry.
The most recent analyst rating on (AU:BUB) stock is a Hold with a A$0.14 price target. To see the full list of analyst forecasts on Bubs Australia Ltd. stock, see the AU:BUB Stock Forecast page.
Bubs Australia Ltd. announced a favorable outcome in a legal dispute involving its subsidiary, The Infant Food Co. Pty Limited, against Alice Trading Limited and Willis Trading Limited, subsidiaries of Alpha Professional Holdings Ltd. The Australian Centre for International Commercial Arbitration awarded Bubs a total of $26.5 million for debt, breach of contract, and damages claims. This outcome strengthens Bubs’ financial position and underscores its ability to successfully navigate complex legal challenges, potentially enhancing its standing in the industry.